NVSEF News and Press, Novartis Ag Basel Akt From 12/13/22

Summary Humira's international sales were $603 million in Q3 2022, down 25.7% year-over-year, and this is mainly due to increased competition from biosimilars in Europe. AbbVie's EBITDA was $7,235 million in Q3 2022, up 2.8% year-on-year. The largest contribution to the company's re...

Summary IQDG is a large-cap, ex-US dividend growth ETF. 79% of asset value is in European companies. It is well-balanced across sectors, but quite concentrated in the top holdings. Past performance is underwhelming relative to its peers. IQDG's strategy and portfolio...

Summary Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high, longer than expected. The pandemic vaccine/antiviral income windfall has moved its balance sheet into a super-conservative and liquid setting. Valua...

Summary Fisher’s 13F portfolio value decreased from ~$141B to ~$133B in Q3 2022. They added Charles Schwab and increased Nvidia, Morgan Stanley, and Goldman Sachs while decreasing Salesforce, Visa, Alibaba Group Holdings, Novartis, Verizon, and Tencent Holdings. The top...

Summary AstraZeneca's revenue was $10,771 million in the 2nd quarter of 2022, showing a 31% increase from the previous year. Over the past three quarters, a slew of AstraZeneca's medicines have received regulatory approvals from the US, Europe, Japan, and China, thereby maintainin...

Summary As a company, Genmab has brought valuable medicines for patients. However, as a stock, it seems to be lagging, waiting for that blockbuster potential to be tapped. I will wait for a better price. I first covered Genmab A/S ( GMAB ) in December 2020, a...

Summary Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA approval, could increase EPS dramatically in future years. Strong ups...

The following slide deck was published by Novartis AG in conjunction with their 2022 Q3 earnings call. For further details see: Novartis AG 2022 Q3 - Results - Earnings Call Presentation

Novartis AG (NVS) Q3 2022 Earnings Conference Call October 25, 2022 08:00 ET Company Participants Samir Shah - Global Head, Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants ...

Summary Novartis reported revenues and earnings that were down year over year. Currency rate movements were responsible for that, however, Novartis' underlying performance was pretty solid. The company offers a nice dividend yield and should be able to deliver very solid retur...